Table II.

Partial inhibition of EAE by systemic administration of cytokine DNA constructs into myoproliferating musclea

TreatmentNo. EAEMean Group Score (±SEM)Mean Day of Onset (±SEM)
SCH22/223.4 ± 0.216.4 ± 0.3
BaC1210/103.5 ± 0.216.0 ± 0.5
p75 dTNFR5/53.6 ± 0.317.6 ± 1.0
p55 TNFR-Ig13/142.6 ± 0.3b16.0 ± 0.4
IL-109/93.1 ± 0.318.3 ± 0.8
TNF9/93.6 ± 0.317.0 ± 0.2
IL-46/62.8 ± 0.518.3 ± 1.0
TGF-β15/153.0 ± 0.216.2 ± 0.4
  • a Animals were injected with SCH in Freund’s adjuvant on days 0 and 7. BaC12 solution (1.2%) was injected i.m. into the anterior tibialis 5 days prior to 100 μg naked DNA coding for p55TNFR-Ig, p75 d-TNFR, IL-10, IL-4, TNF, and TGF-β injected i.m. on day 0. The results represent the mean ± SEM maximum clinical score of all animals within the group and the mean day of onset of the animals that developed EAE.

  • b p < 0.05 compared to animals injected with SCH only.